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A B S T R A C T
Purpose: The present study aimed to compare the serum LTG levels during the early-/mid-follicular (low
estradiol) and mid-luteal (high estradiol) phases of the physiologic menstrual cycle.
Method: In a cross-sectional study, 20 women with epilepsy were recruited. Participants had been on
monotherapy with LTG for at least two months. All the subjects had normal menstrual cycles. Blood
samples for each patient were taken whilst fasting during the early-/mid-follicular (Days 3–5) and mid-
luteal phases (Days 20–24). All samples were analyzed in batched assays. A comparison of the serum LTG
levels was carried out using the Mann–Whitney U test Data were analyzed with the SPSS program,
version 16 (SPSS Inc., Chicago, IL), p-values below 0.05 were considered signiﬁcant.
Results: The mean serum LTG levels for the early-/mid-follicular and mid-luteal phases were
4.28  2.76 mg/ml (SD) and 3.86  2.06 mg/ml (SD), respectively. There was no statistically signiﬁcant
difference in serum LTG level between the (low estradiol) early-/mid-follicular and (high estradiol) mid-
luteal phases in our patients (p-value = 0.23).
Conclusion: The serum level of LTG does not alter signiﬁcantly during the menstrual cycle.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Lamotrigine (LTG) is a broad-spectrum antiepileptic drug (AED)
used to treat various types of epilepsy and psychiatric disorders. In
comparison with older AEDs, LTG has been recognized as a drug
with only a few side effects during pregnancy. Some of the few
reported side effects of LTG are folic acid deﬁciency and neonatal
withdrawal. There is also a small risk of sexual or reproductive
dysfunction associated with LTG. Therefore it is a preferable choice
for females of childbearing age [1]. LTG is not biotransformed by
the hepatic cytochrome P450 system. Instead, it is metabolized
almost exclusively by uridine diphosphate glucuronosyltransfer-
ase (UGT) enzymes [2]. It has been shown that estrogenic
substrates are also metabolized by glucuronidation, and may
potentially interact with the metabolism of LTG [3].
Some studies have indicated that oral contraceptives may increase
the metabolism of LTG, resulting in a signiﬁcant decrease in the plasma
concentration of LTG [4,5]. This effect is probably related to the ethinyl* Corresponding author. Tel.: +98 9122493628; fax: +98 2155417547.
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relatively well-documented effects of the ethinyl estradiol content of
combined contraceptive pills on LTG level, there have been few studies
regarding the effect of hormonal changes during the physiological
menstrual cycle on serum LTG concentration.
The present study aimed to compare the serum LTG levels
during the early-/mid-follicular (low estradiol) and mid-luteal
(high estradiol) phases of the physiologic menstrual cycle.
2. Method
Over a three-month period between December 2014 and
February 2015, as part of a cross-sectional study, 20 women with
epilepsy—who were attended the neurology clinic of an urban
teaching hospital (Loghman Hakim Hospital)—were recruited.
Participants had been on monotherapy with LTG for at least two
months. All the subjects had normal menstrual cycles, deﬁned as
regular cycles lasting 21–35 days. The exclusion criteria were
pregnancy, age of under 18 years, consumption of any hormonal
contraceptives or antiepileptic medication except LTG, endocrine
diseases, breastfeeding, abnormal liver or renal functioning, and
abnormal menstrual cycle.served.
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minimize the possible ﬂuctuation of serum LTG level. The
individual doses were held unchanged throughout the study.
Blood samples for each patient were taken whilst fasting in the
morning (between 8 and 9 AM) before the morning dose, during
the early-/mid-follicular (Days 3–5) and mid-luteal phases (Days
20–24). Total serum LTG levels were measured in the same
laboratory by high-performance liquid chromatography. To reduce
variability, all samples were analyzed in batched assays (ARK
Diagnostics, Inc., Fremont, CA). A comparison of the serum LTG
levels from the follicular phases and the luteal phase was carried
out using the Mann–Whitney U test. Patients were informed
regarding the study protocol and written consent was obtained.
Data were analyzed with the SPSS program, version 16 (SPSS Inc.,
Chicago, IL), and p-values below 0.05 were considered signiﬁcant.
3. Results
Fourteen of the participants had generalized epilepsy and six
had focal seizures. Fourteen patients had less than one seizure
attack per year, while the other six had more than one seizure
attack in a year. Eight cases had been experiencing seizures for less
than one year, in another eight cases one-to-ﬁve years, and in the
ﬁnal four cases over ﬁve years. The characteristics of the patients
are summarized in Table 1.
The mean serum LTG levels for the early-/mid-follicular and
mid-luteal phases were 4.28  2.76 mg/ml (SD) and 3.86  2.06 mg/
ml (SD), respectively. There was no statistically signiﬁcant difference
in serum LTG level between the (low estradiol) early-/mid-follicular
and (high estradiol) mid-luteal phases in our patients (p-val-
ue = 0.23). The maximal and minimal differences between serum
LTG concentrations in the luteal and follicular phases, in a single
participant, were 0.45 mg/dl and 1.04 mg/dl, respectively, which was
not clinically signiﬁcant (p-value = 1.96).
4. Discussion
LTG is increasingly used worldwide for both epileptic and
psychiatric disorders. Unlike most other antiepileptic drugs, the
major route (76%) of elimination of LTG is through conjugation
with glucuronidation. This conjugation reaction is catalyzed by
uridine diphosphate glucuronosyltransferase [3].
In previous studies, it has been shown that combined oral
contraceptives can reduce LTG serum concentration up to 64%
[6]. This could be explained by the fact that the estrogenic contents
of oral contraceptives are metabolized by glucuronidation [3]. In
another study, a 116% increase in LTG plasma concentration
was observed, seven days after beginning a treatment period with
combined oral contraceptives [5]. However, progesterone-only
contraceptive compounds do not reduce LTG serum concentration
[6]. Moreover, it has been reported that the serum level-to-doseTable 1
Clinical characteristics of the patients.
Number of subjects 20
Age (years) 28  4a
Duration of menstrual cycle (days) 30  5
Type of epilepsy Focal (n = 6)
Generalized (n = 14)
Lamotrigine dose (mg/day) 300 (225–375)
Follicular phase serum LTGb (mg/ml) 4.28  2.76
Luteal phase serum LTG (mg/ml) 3.86  2.06
Last LTG dose to sampling time (hour) 11  1
a Mean  SD.
b LTG, lamotrigine.ratio of LTG may decrease by 40% during pregnancy, probably
because of an increased plasma clearance of LTG induced by
hormonal changes during pregnancy [7].
There have been few studies into the effects of hormonal
changes on serum LTG concentration during the physiologic
menstrual cycle. In one study, performed by Herzog et al. on
12 women with epilepsy using LTG, a notable but not signiﬁcant
31.3% median decline was observed during the mid-luteal phase,
compared to the early-/mid-follicular phase, in patients who did
not use any oral contraceptives [8]. However, we found that
normal estrogenic hormonal ﬂuctuation during the physiologic
menstrual cycle does not alter the serum LTG concentration.
Indeed, our results are consistent with a number of other reports.
In a study that was performed on just two cases, by Reimers et al.,
the physiologic ﬂuctuations of female sex hormones throughout a
normal menstrual cycle were not found to be associated with
relevant changes in LTG serum concentration [2]. In another study,
three groups of women with epilepsy using LTG monotherapy
were evaluated: the ﬁrst group (n = 7) did not use oral contra-
ceptives; the second group used oral contraceptives (n = 7); and
the third group (n = 7) was postmenopausal. Two menstrual cycles
were assessed, monitoring LTG levels every other day. There was a
higher mean LTG clearance in postmenopausal women, compared
with young women not using oral contraceptives. However, their
study also showed that there was no signiﬁcant ﬂuctuation of LTG
clearance during the menstrual cycle [1].
The hypothesis has been proposed that, unlike synthetic
ethinyl estradiols, natural ones may minimally affect the level
of LTG metabolism [8]. Another suggested hypothesis is that the
effect of estradiol on LTG may require a much higher estradiol
serum concentration than those achieved during a normal
menstrual cycle, or during hormone replacement therapy
[9]. However, given the conﬂicting data from other studies, it is
difﬁcult to fully support this hypothesis, meaning more research is
needed in this context [2].
During pregnancy, the estradiol serum concentration increases
by up to 30 times that of the normal level in the menstrual cycle.
This effect can result in a signiﬁcant decrease in LTG concentration
during pregnancy [2]. However, several other physiologic changes
during pregnancy may affect the metabolism of LTG. In comparison
with other AEDs, the changes to LTG clearance are signiﬁcant
[11]. Harden et al. have reported a 94% increase in total LTG
clearance, and an 89% rise in free LTG clearance, during pregnancy
[12]. In addition, pregnancy causes changes in drug pharmacoki-
netics, drug absorption, and metabolism. Therefore it would be
prudent to actively monitor AED levels, in particular that of LTG, in
pregnant woman with epilepsy [12].
5. Conclusion
It seems that the serum level of LTG does not alter signiﬁcantly
during the menstrual cycle. Furthermore, it lacks the risk of sexual
dysfunction observed in association with other AEDs [10]. Such
advantages should be considered in drug selection for women with
epilepsy.
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